

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:664US/TJSSerial No.  
09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.  
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
June 21, 2000Group:  
1645 *1616*U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

TECH CENTER 1600/2900

JUN 11 2001

RECEIVED

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>dg</i>	C1	Abrams <i>et al.</i> , "Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats," <i>J. Nucl. Med.</i> , 31:2022-2028, 1990.
	C2	Bakker <i>et al.</i> , "Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals," <i>J. Nucl. Med.</i> , 31:1501-1509, 1990.
	C3	Blakenberg <i>et al.</i> , "Imaging of apoptosis (programmed cell death) with <sup>99m</sup> Tc annexin V," <i>J. Nucl. Med.</i> , 40:184-191, 1999.
	C4	Blondeau <i>et al.</i> , "Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid," <i>Can J. Chem.</i> , 45:49-52, 1967.
	C5	Davison <i>et al.</i> , "A new class of oxotechnetium(5+) chelate complexes containing a TcON <sub>2</sub> S <sub>2</sub> Core," <i>Inorg Chem.</i> , 20:1629-1632, 1981.
	C6	Goldsmith <i>et al.</i> , "Somatostatin receptor imaging in lymphoma," <i>Sem Nucl Med.</i> , 25:262-271, 1995.
	C7	Goldsmith, "Receptor imaging: Competitive or complementary to antibody imaging," <i>Sem Nucl Med.</i> , 27:85-93, 1997.
<i>dg</i>	C8	Hadley <i>et al.</i> , "Magnetic resonance imaging in acute head injury," <i>Clin. Rad.</i> , 39:131-139, 1988.

25027393.1

EXAMINER:

*D. Jones*

DATE CONSIDERED:

*4/19/02*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664US/TJS

09/599,152

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

Filing Date:

June 21, 2000

Group:

1645

Other Art

See Page 1

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Jamar <i>et al.</i> , "Clearance of the new tubular agent Tc-99m L,L-ethylenedicycysteine: Estimation by a simplified method," <i>J Nucl Med</i> , 34:129P, 1993.
	C10	Jamar <i>et al.</i> , "Clinical evaluation of Tc-99m L,L-ethylenedicycysteine, a new renal tracer, in transplanted patients," <i>J Nucl Med</i> , 34:129P, 1993a.
	C11	Kabasakal. "Technetium-99m ethylene dicycysteine: a new renal tubular function agent," <i>Eur. J Nucl. Med.</i> 27:351-357, 2000.
	C12	Koh <i>et al.</i> , "Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole," <i>Int J Radiat Oncol Biol Phys</i> , 22:199-212, 1992.
	C13	Leamon and Low, "Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis," <i>Proc Natl Acad Sci</i> , 88:5572-5576, 1991.
	C14	Lee <i>et al.</i> , "Prognostic value of single-photon emission tomography in acute ischaemic stroke," <i>Eur. Journ. Nuc. Med.</i> , 24:21-26, 1989.
	C15	Maraganore <i>et al.</i> , "Structure of the hirugen and hirulog 1 complexes of $\alpha$ -thrombin," <i>J. Mol. Biol.</i> , 221:1379-1393, 1991.
	C16	Martin <i>et al.</i> , "Enhanced binding of the hypoxic cell marker [ $^3$ H]fluoromisonidazole in ischemic myocardium," <i>J Nucl Med</i> , 30:194-201, 1989.
	C17	Mathias <i>et al.</i> , "Indium-111-DTPA-folate as a radiopharmaceutical for targeting tumor-associated folate binding protein," <i>J Nucl Med</i> , (Supplement) 38:133P, 1997.
	C18	Mathias <i>et al.</i> , "Synthesis of Tc-99m-DTPA-folate and preliminary evaluation as a folate-receptor-targeted radiopharmaceutical," <i>J Nucl Med</i> , (Supplement); 38:87P, 1997.
	C19	Mathias <i>et al.</i> , "Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium-67-deferoxamine-folate," <i>J Nucl Med</i> , 37:1003-1008, 1996.
	C20	Olson <i>et al.</i> , "Radiolabeling of fibrinogen using the lodogen technique," <i>Throm. Res. Cen. Dept. Biochem.</i> , pp 593-596, 1982.
	C21	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int. J. Radiat Oncol. Biol Phys</i> , 17:985-991, 1989.
	C22	Rasey <i>et al.</i> , "Characterization of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiat Res</i> , 122:301-308, 1990.


25027393.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

RECEIVED  
JUN 11 2001

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:664US/TJSSerial No.  
09/599,152

Office of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.  
Edmund Kim

Filing Date:

June 21, 2000

Group:

1645

Other Art

See Page 1

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
DA	C23	Knight <i>et al.</i> , "Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets," <i>J. Nucl. Med.</i> , 35:282-288, 1991.
	C24	Seabold <i>et al.</i> , "Comparison of <sup>99m</sup> Tc-Methoxyisobutyl Isonitrile and <sup>201</sup> Tl Scintigraphy for Detection of Residual Thyroid Cancer After <sup>131</sup> I Ablative Therapy," <i>J. Nucl. Med.</i> , 40(9):1434-1440, 1999.
	C25	<del>Walters</del> Sobel <i>et al.</i> , "Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction," <i>J. Nucl. Med.</i> , 30:1798-1808, 1989.
	C26	<del>Stuttig</del> King <i>et al.</i> , "Imaging of bone infection with labelled white blood cells: role of contemporaneous bone marrow imaging," <i>Dept. Dia. Rad.</i> , pp 148-151, 1990.
	C27	Surma <i>et al.</i> , "Usefulness of Tc-99m-N,N'-ethylene-1-dicysteine complex for dynamic kidney investigations," <i>Nucl Med Comm</i> , 15:628- 635, 1994.
	C28	Tubis <i>et al.</i> , "The preparation of <sup>99m</sup> technetium-labelled cystine, methionine and synthetic polypeptide and their distribution in mice," <i>Int. Journ. Appl. Rad. Isotop.</i> , 19:835-840, 1968.
	C29	Valk <i>et al.</i> , "Hypoxia in human gliomas: Demonstration by PET with [ <sup>18</sup> F]fluoromisonidazole," <i>J Nucl Med</i> , 33:2133-2137, 1992.
	C30	Van Nerom <i>et al.</i> , "Comparative evaluation of Tc-99m L,L-ethylenedicysteine and Tc-99m MAG3 in volunteers," <i>Eur J Nucl Med</i> , 16:417, 1990.
	C31	Van Nerom <i>et al.</i> , "First experience in healthy volunteers with Tc-99m-L,L-ethylenedicysteine, a new renal imaging agent," <i>Eur J Nucl Med</i> , 20:738-746, 1993.
	C32	Verbruggen <i>et al.</i> , "Evaluation of Tc-99m-L,L-ethylenedicysteine as a potential alternative to Tc-99m MAG3," <i>Eur J Nucl Med</i> , 16:429, 1990.
	C33	Verbruggen <i>et al.</i> , "Tc-99m-L,L-ethylenedicysteine: A renal imaging agent. I. Labelling and evaluation in animals," <i>J Nucl Med</i> , 33:551-557, 1992.
	C34	Wang <i>et al.</i> , "Design and synthesis of [ <sup>111</sup> In]DTPA-folate for use as a tumor-targeted radiopharmaceutical," <i>Bioconjugate Chem</i> , 8:673-679, 1997.
DA	C35	Wang <i>et al.</i> , "Synthesis, purification, and tumor cell uptake of Ga-67 deferoxamine-folate, a potential radiopharmaceutical for tumor imaging," <i>Bioconjugate Chem</i> , 7:56- 62, 1996.

25027393.1

EXAMINER:

D. Jones

DATE CONSIDERED:

4/19/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:664US/TJSSerial No.  
09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.  
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

Filing Date:  
June 21, 2000

Group:

1645

1616

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>RD</i>	C36	Yang <i>et al.</i> , "Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia," <i>Radiology</i> , 194:795-800, 1995.

25027393.1

EXAMINER:

*RD Jones*

DATE CONSIDERED:

*4/19/02*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)